Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | MicrobiomeTrials← Back to trialsNCT05997615
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-08-10Est. Completion: 2027-09-29
Enrollment target: 437 participants Locations- UCI Health Chao Family Comprehensive Cancer Center, Orange, California, United States
- Investigational Site Number: 403, Palo Alto, California, United States
- Investigational Site Number: 401, Houston, Texas, United States
- Investigational Site number: 404, Fairfax, Virginia, United States
- Investigational Site Number: 400, Seattle, Washington, United States
- Investigational Site Number: 100, Melbourne, Australia
- Investigational Site Number: 101, Sydney, Australia
- Investigational Site Number: 251, Barcelona, Spain
- Investigational Site Number: 250, Barcelona, Spain
- Investigational Site Number: 254, Madrid, Spain
- Investigational Site Number: 252, Madrid, Spain
- Investigational Site Number: 253, Pamplona, Spain
- Investigational Site Number: 300, London, United Kingdom
Other microbiome trials you might be interested in
Castrate Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate CancerProstate Carcinoma
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy wi…
San Francisco, United StatesEst. completion May 31, 2027
Prostate Cancer Metastatic
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metas…
Redwood City, United StatesEst. completion Oct 2028